|
1
|
Baumgart DC and Carding SR: Inflammatory
bowel disease: Cause and immunobiology. Lancet. 369:1627–1640.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xavier RJ and Podolsky DK: Unravelling the
pathogenesis of inflammatory bowel disease. Nature. 448:427–434.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baumgart DC and Sandborn WJ: Inflammatory
bowel disease: Clinical aspects and established and evolving
therapies. Lancet. 369:1641–1657. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nielsen OH: New strategies for treatment
of inflammatory bowel disease. Front Med (Lausanne). 1:32014.
|
|
5
|
Danese S: New therapies for inflammatory
bowel disease: From the bench to the bedside. Gut. 61:918–932.
2012. View Article : Google Scholar
|
|
6
|
Hilsden RJ, Verhoef MJ, Rasmussen H,
Porcino A and DeBruyn JC: Use of complementary and alternative
medicine by patients with inflammatory bowel disease. Inflamm Bowel
Dis. 17:655–662. 2011. View Article : Google Scholar
|
|
7
|
Langmead L and Rampton DS: Review article:
Complementary and alternative therapies for inflammatory bowel
disease. Aliment Pharmacol Ther. 23:341–349. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rahimi R, Mozaffari S and Abdollahi M: On
the use of herbal medicines in management of inflammatory bowel
diseases: A systematic review of animal and human studies. Dig Dis
Sci. 54:471–480. 2009. View Article : Google Scholar
|
|
9
|
Jackson LN, Zhou Y, Qiu S, Wang Q and
Evers BM: Alternative medicine products as a novel treatment
strategy for inflammatory bowel disease. Am J Chin Med. 36:953–965.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sałaga M, Zatorski H, Sobczak M, Chen C
and Fichna J: Chinese herbal medicines in the treatment of IBD and
colorectal cancer: A review. Curr Treat Options Oncol. 15:405–420.
2014. View Article : Google Scholar
|
|
11
|
Li R, Alex P, Ye M, Zhang T, Liu L and Li
X: An old herbal medicine with a potentially new therapeutic
application in inflammatory bowel disease. Int J Clin Exp Med.
4:309–319. 2011.PubMed/NCBI
|
|
12
|
Cao YB, Zhang JD, Diao YY, Yan L, Wang DJ,
Jia XM, Gao PH, Cheng MH, Xu Z, Wang Y and Jiang YY: Effects of
Changtai granules, a traditional compound Chinese medicine, on
chronic trinitrobenzene sulfonic acid-induced colitis in rats.
World J Gastroenterol. 11:3539–3543. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sandborn WJ, Targan SR, Byers VS, Rutty
DA, Mu H, Zhang X and Tang T: Andrographis paniculata extract
(HMPL-004) for active ulcerative colitis. Am J Gastroenterol.
108:90–98. 2013. View Article : Google Scholar :
|
|
14
|
Zhang F, Li Y, Xu F, Chu Y and Zhao W:
Comparison of Xilei-san, a Chinese herbal medicine and
dexamethasone in mild/moderate ulcerative proctitis: A double-blind
randomized clinical trial. J Altern Complement Med. 19:838–842.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu Y, Chen X, Duan H, Hu Y and Mu X:
Pulsatilla decoction and its active ingredients inhibit secretion
of NO, ET-1, TNF-alpha and IL-1 alpha in LPS-induced rat intestinal
microvascular endothelial cells. Cell Biochem Funct. 27:284–288.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng L, Zhang M, Zhang P, Song Z, Ma Z
and Qu H: Silver complexation and tandem mass spectrometry for
differentiation of triterpenoid saponins from the roots of
Pulsatilla Chinensis (Bunge) Regel. Rapid Commun Mass Spectrom.
22:3783–3790. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tan B, Ma Y, Shi R and Wang T:
Simultaneous quantification of three alkaloids of Coptidis Rhizoma
in rat urine by high-performance liquid chromatography: Application
to pharmacokinetic study. Biopharm Drug Dispos. 28:511–516. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chan CO, Chu CC, Mok DK and Chau FT:
Analysis of berberine and total alkaloid content in cortex
phellodendri by near infrared spectroscopy (NIRS) compared with
high-performance liquid chromatography coupled with ultra-visible
spectrometric detection. Anal Chim Acta. 592:121–131. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shi Z, Zhu X and Zhang H: Micelle-mediated
extraction and cloud point preconcentration for the analysis of
aesculin and aesculetin in Cortex fraxini by HPLC. J Pharm Biomed
Anal. 44:867–873. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muluye RA, Bian Y and Alemu PN:
Anti-inflammatory and antimicrobial effects of heat-clearing
Chinese herbs: A current review. J Tradit Complement Med. 4:93–98.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heller F, Fuss IJ, Nieuwenhuis EE,
Blumberg RS and Strober W: Oxazolone colitis, a Th2 colitis model
resembling ulcerative colitis, is mediated by IL-13-producing NK-T
cells. Immunity. 17:629–638. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals: Guide for the care and use of laboratory animals. 8th
edition. National Academies Press; Washington, D.C., USA: 2011
|
|
23
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
León AJ, Gómez E, Garrote JA, Bernardo D,
Barrera A, Marcos JL, Férnandez-Salazar L, Velayos B, Blanco-Quirós
A and Arranz E: High levels of proinflammatory cytokines, but not
markers of tissue injury, in unaffected intestinal areas from
patients with IBD. Mediators Inflamm. 2009:302009. View Article : Google Scholar
|
|
25
|
Imbert V, Rupec RA, Livolsi A, Pahl HL,
Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger
P, Baeuerle PA and Peyron JF: Tyrosine phosphorylation of I kappa
B-alpha activates NF-kappa B without proteolytic degradation of I
kappa B-alpha. Cell. 86:787–798. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kojima R, Kuroda S, Nakamaru K and
Hatakeyama S: Oxazolone-induced colitis in BALB/C mice: A new
method to evaluate the efficacy of therapeutic agents for
ulcerative colitis. J Pharmacol Sci. 96:307–313. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Svartz N: Salazopyrin a new sulfanilamide
preparation: A. Therapeutic results in rheumatic polyarthritis. B.
Therapeutic results in ulcerative colitis. C. Toxic manifestations
in treatment with sulfanilamide preparation. Acta Med Scand.
11:557–590. 1942.
|
|
28
|
Kornbluth A and Sachar DB; Practice
Parameters Committee of the American College of Gastroenterology:
Ulcerative colitis practice guidelines in adults: American college
of gastroenterology, practice parameters committee. Am J
Gastroenterol. 105:501–523; quiz 524. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khor B, Gardet A and Xavier RJ: Genetics
and pathogenesis of inflammatory bowel disease. Nature.
474:307–317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Strober W and James SP: The immunologic
basis of inflammatory bowel disease. J Clin Immunol. 6:415–432.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fuss IJ, Neurath M, Boirivant M, Klein JS,
de la Motte C, Strong SA, Fiocchi C and Strober W: Disparate CD4+
lamina propria (LP) lymphokine secretion profiles in inflammatory
bowel disease. Crohn's disease LP cells manifest increased
secretion of IFN-gamma, whereas ulcerative colitis LP cells
manifest increased secretion of IL-5. J Immunol. 157:1261–1270.
1996.PubMed/NCBI
|
|
32
|
Heller F, Florian P, Bojarski C, Richter
J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, Burgel N, Fromm
M, et al: Interleukin-13 is the key effector Th2 cytokine in
ulcerative colitis that affects epithelial tight junctions,
apoptosis and cell restitution. Gastroenterology. 129:550–564.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hering NA, Fromm M and Schulzke JD:
Determinants of colonic barrier function in inflammatory bowel
disease and potential therapeutics. J Physiol. 590:1035–1044. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Suzuki T: Regulation of intestinal
epithelial permeability by tight junctions. Cell Mol Life Sci.
70:631–659. 2013. View Article : Google Scholar
|
|
35
|
Turner JR: Intestinal mucosal barrier
function in health and disease. Nat Rev Immunol. 9:799–809. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Weber CR, Raleigh DR, Su L, Shen L,
Sullivan EA, Wang Y and Turner JR: Epithelial myosin light chain
kinase activation induces mucosal interleukin-13 expression to
alter tight junction ion selectivity. J Biol Chem. 285:12037–12046.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Prasad S, Mingrino R, Kaukinen K, Hayes
KL, Powell RM, MacDonald TT and Collins JE: Inflammatory processes
have differential effects on claudins 2, 3 and 4 in colonic
epithelial cells. Lab Invest. 85:1139–1162. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schreiber S, Nikolaus S and Hampe J:
Activation of nuclear factor kappa B inflammatory bowel disease.
Gut. 42:477–484. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Neurath MF, Becker C and Barbulescu K:
Role of NF-kappaB in immune and inflammatory responses in the gut.
Gut. 43:856–860. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ma TY, Iwamoto GK, Hoa NT, Akotia V,
Pedram A, Boivin MA and Said HM: TNF-alpha-induced-induced increase
in intestinal epithelial tight junction permeability requires
NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol.
286:G367–G376. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Beutheu Youmba S, Belmonte L, Galas L,
Boukhettala N, Bôle-Feysot C, Déchelotte P and Coëffier M:
Methotrexate modulates tight junctions through NF-κB, MEK, and JNK
Pathways. J Pediatr Gastroenterol Nutr. 54:463–470. 2012.
View Article : Google Scholar
|
